STI incidence up after receipt of HIV preexposure prophylaxis

STI incidence up after receipt of HIV preexposure prophylaxis

(HealthDay)—For gay and bisexual men, receipt of HIV preexposure prophylaxis (PrEP) is associated with an increase in sexually transmitted infections (STIs), according to a study published in the April 9 issue of the Journal of the American Medical Association.

Michael W. Traeger, from the Burnet Institute in Melbourne, Australia, and colleagues describe STI incidence and among a cohort of 2,981 predominantly gay and bisexual men (98.5 percent) who use PrEP. Participants received daily oral tenofovir disoproxil fumarate and emtricitabine for HIV PrEP upon , quarterly HIV and STI testing, and clinical monitoring.

The researchers found that 2,928 STIs were diagnosed among 1,427 (48 percent) during a mean follow-up of 1.1 years. The incidence of STIs was 91.9 per 100 person-years, with 25 percent of participants accounting for 76 percent of all STIs. Younger age, greater partner number, and group sex were associated with greater STI risk, but condom use was not, among 2,058 participants with complete data for multivariable analysis. From before enrollment to follow-up, the incidence of STIs increased from 69.5 to 98.4 per 100 person-years (incidence rate ratio [IRR], 1.41). The increase in incidence from one year before enrollment to follow-up was significant for any STI and for chlamydia (adjusted IRRs, 1.12 and 1.17, respectively).

"These findings highlight the importance of frequent STI testing among gay and using PrEP," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2019 HealthDay. All rights reserved.

Citation: STI incidence up after receipt of HIV preexposure prophylaxis (2019, April 10) retrieved 28 September 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Protection against HSV-2 is added benefit of tenofovir


Feedback to editors